{"id":"NCT05296629","sponsor":"Journey Medical Corporation","briefTitle":"A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-03-14","primaryCompletion":"2023-06-30","completion":"2023-06-30","firstPosted":"2022-03-25","resultsPosted":"2024-12-03","lastUpdate":"2024-12-03"},"enrollment":323,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"DFD-29","otherNames":[]},{"type":"DRUG","name":"Doxycycline","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"DFD-29","type":"EXPERIMENTAL"},{"label":"Doxycycline 40 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.","primaryOutcome":{"measure":"Investigator's Global Assessment (IGA) Treatment Success Compared to Placebo.","timeFrame":"Baseline to Week 16.","effectByArm":[{"arm":"DFD-29","deltaMin":79,"sd":null},{"arm":"Placebo","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":["40042869"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":121},"commonTop":["COVID-19","Nasopharyngitis","Headache","Diarrhea","Nausea"]}}